190 related articles for article (PubMed ID: 7693327)
21. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results.
Oberg K; Norheim I; Lind E; Alm G; Lundqvist G; Wide L; Jonsdottir B; Magnusson A; Wilander E
Cancer Treat Rep; 1986 Nov; 70(11):1297-304. PubMed ID: 2429764
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.
Di Bartolomeo M; Bajetta E; Bochicchio AM; Carnaghi C; Somma L; Mazzaferro V; Visini M; Gebbia V; Tumolo S; Ballatore P
Ann Oncol; 1995 Jan; 6(1):77-9. PubMed ID: 7710986
[TBL] [Abstract][Full Text] [Related]
23. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
Kelly K; Crowley JJ; Bunn PA; Hazuka MB; Beasley K; Upchurch C; Weiss GR; Hicks WJ; Gandara DR; Rivkin S
J Clin Oncol; 1995 Dec; 13(12):2924-30. PubMed ID: 8523056
[TBL] [Abstract][Full Text] [Related]
24. Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumours.
Zhou Y; Gobl A; Wang S; Jacobsen MB; Janson ET; Haines GK; Radosevich JA; Oberg K
Eur J Cancer; 1998 Dec; 34(13):2046-52. PubMed ID: 10070309
[TBL] [Abstract][Full Text] [Related]
25. Interferons in the management of neuroendocrine tumors and their possible mechanism of action.
Oberg K
Yale J Biol Med; 1992; 65(5):519-29; discussion 531-6. PubMed ID: 1340065
[TBL] [Abstract][Full Text] [Related]
26. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
[TBL] [Abstract][Full Text] [Related]
27. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
[TBL] [Abstract][Full Text] [Related]
28. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
Kataja V; Yap A
Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
[TBL] [Abstract][Full Text] [Related]
29. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
30. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
33. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.
Lippman SM; Kavanagh JJ; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong WK; Holdener E; Krakoff IH
J Natl Cancer Inst; 1992 Feb; 84(4):241-5. PubMed ID: 1734085
[TBL] [Abstract][Full Text] [Related]
34. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial.
Janson ET; Rönnblom L; Ahlström H; Grandér D; Alm G; Einhorn S; Oberg K
Ann Oncol; 1992 Sep; 3(8):635-8. PubMed ID: 1450046
[TBL] [Abstract][Full Text] [Related]
35. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors.
Oberg K; Eriksson B; Janson ET
Digestion; 1994; 55 Suppl 3():64-9. PubMed ID: 7698540
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease.
Georgiou S; Monastirli A; Pasmatzi E; Gartaganis S; Goerz G; Tsambaos D
J Intern Med; 1998 May; 243(5):367-72. PubMed ID: 9651559
[TBL] [Abstract][Full Text] [Related]
37. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
Kankuri M; Pelliniemi TT; Pyrhönen S; Nikkanen V; Helenius H; Salminen E
Cancer; 2001 Aug; 92(4):761-7. PubMed ID: 11550145
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
Zouboulis CC; Orfanos CE
Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
